168. Ehlers-Danlos syndrome Clinical trials / Disease details


Clinical trials : 13 Drugs : 21 - (DrugBank : 11) / Drug target genes : 11 - Drug target pathways : 103

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05463679
(ClinicalTrials.gov)
January 20246/4/2022Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome (vEDS) Confirmed With COL3A1 Mutations, Followed by an Open Label Extension (OLE)Vascular Ehlers-Danlos SyndromeDrug: Enzastaurin;Drug: PlaceboAytu BioPharma, Inc.ParexelSuspended18 Years60 YearsAll260Phase 3United States
2NCT05603741
(ClinicalTrials.gov)
November 10, 202224/10/2022Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy VolunteersLocal Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy VolunteersEhlers-Danlos Syndrome;Anesthesia, LocalDrug: 0.9% Sodium Chloride Injection;Drug: Lidocaine Injection 2%University of CalgaryVanderbilt University Medical CenterActive, not recruiting18 YearsN/AAll155Phase 4Canada
3NCT05432466
(ClinicalTrials.gov)
November 7, 202221/6/2022Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos SyndromeA Phase 3 Randomized, Double-Blind, Decentralized Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in the Treatment of Patients With COL3A1-Positive Vascular Ehlers-Danlos SyndromeVascular Ehlers-Danlos SyndromeDrug: ACER-002 (celiprolol) 200 mg BID;Drug: Placebo BIDAcer Therapeutics Inc.NULLRecruiting15 Years64 YearsAll150Phase 3United States
4NCT05405257
(ClinicalTrials.gov)
May 13, 20222/6/2022Oxytocin for Hypermobile Ehlers-Danlos SyndromeOxytocin Treatment for Chronic Pain in Hypermobile Ehlers-Danlos SyndromeHypermobile Ehlers-Danlos Syndrome;Pain AssessmentDrug: Oxytocin;Other: PlaceboBaylor College of MedicineNULLEnrolling by invitation18 Years64 YearsFemale20Phase 1/Phase 2United States
5NCT04890431
(ClinicalTrials.gov)
June 20216/5/2021Impact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos SyndromeImpact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos Syndrome: a Randomised Double-blind Placebo-controlled StudyEhlers-Danlos SyndromeDrug: Oxygen;Drug: PlaceboHospital St. Joseph, Marseille, FranceNULLNot yet recruiting18 YearsN/AAll82Phase 4NULL
6NCT04036305
(ClinicalTrials.gov)
July 26, 201925/7/2019Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy VolunteersLocal Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy VolunteersEhlers-Danlos Syndrome;Anesthesia, LocalDrug: 0.9% Sodium Chloride Injection;Drug: Lidocaine Injection 2%;Drug: Bupivacaine Injection 0.5%Vanderbilt University Medical CenterUniversity of CalgaryEnrolling by invitation18 YearsN/AAll230United States
7NCT02597361
(ClinicalTrials.gov)
January 201623/10/2015Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial.Ehlers-Danlos Syndrome, Vascular TypeDrug: Irbesartan;Drug: PlaceboAssistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompleted18 Years70 YearsAll61Phase 3France
8EUCTR2015-001065-76-FR
(EUCTR)
28/09/201508/09/2015N/AN/A - ARCADE
MedDRA version: 18.0;Level: PT;Classification code 10014316;Term: Ehlers-Danlos syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders
Trade Name: IRBESARTAN
Product Name: IRBESARTAN
INN or Proposed INN: irbesartan
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLNot RecruitingFemale: yes
Male: yes
169Phase 3France
9NCT01446783
(ClinicalTrials.gov)
September 201127/9/2011IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos PatientsIGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos PatientsEhlers-Danlos Syndrome, ClassicDrug: mecasermin;Drug: SalineBispebjerg HospitalNULLCompleted18 YearsN/ABoth15N/ADenmark
10NCT01307527
(ClinicalTrials.gov)
November 20081/3/2011Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VIBrittle Cornea Syndrome;Ehlers-Danlos Syndrome Type 6Drug: Riboflavin;Device: Kera-XHadassah Medical OrganizationNULLEnrolling by invitation18 YearsN/ABoth1N/AIsrael
11NCT00190411
(ClinicalTrials.gov)
October 200313/9/2005Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular TypePrevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos SyndromeEHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT;CHROMOSOME 2q31.2 DELETION SYNDROMEDrug: celiprolol;Drug: ControlAssistance Publique - Hôpitaux de ParisAventis PharmaceuticalsCompleted15 Years65 YearsBoth54Phase 4France
12NCT00001966
(ClinicalTrials.gov)
January 200018/1/2000Mind-Body Therapy for Pain in Ehlers-Danlos SyndromeA Pilot Study of Mind-Body Therapy for Chronic Pain in Ehlers-Danlos SyndromeEhlers-Danlos Syndrome;PainDrug: Mind-body therapyNational Human Genome Research Institute (NHGRI)NULLCompletedN/AN/ABoth40Phase 2United States
13EUCTR2021-006574-23-NL
(EUCTR)
25/04/2022A study to investigate the efficacy, safety, and pharmacokinetics (PK) of enzastaurin for the prevention of arterial events in patients with vEDS confirmed with COL3A1 mutationsA multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations, followed by an open label extension (OLE) - PREVEnt (Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome Trial) vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations
MedDRA version: 20.0;Level: PT;Classification code 10014316;Term: Ehlers-Danlos syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: Enzastaurin
Product Code: AR101
INN or Proposed INN: Enzastaurin
Other descriptive name: ENZASTAURIN HYDROCHLORIDE
Aytu BioPharma, Inc.NULLNAFemale: yes
Male: yes
260Phase 3France;United States;Belgium;Netherlands;United Kingdom;Sweden